Literature DB >> 7604170

Five-hundred life-saving interventions and their cost-effectiveness.

T O Tengs1, M E Adams, J S Pliskin, D G Safran, J E Siegel, M C Weinstein, J D Graham.   

Abstract

We gathered information on the cost-effectiveness of life-saving interventions in the United States from publicly available economic analyses. "Life-saving interventions" were defined as any behavioral and/or technological strategy that reduces the probability of premature death among a specified target population. We defined cost-effectiveness as the net resource costs of an intervention per year of life saved. To improve the comparability of cost-effectiveness ratios arrived at with diverse methods, we established fixed definitional goals and revised published estimates, when necessary and feasible, to meet these goals. The 587 interventions identified ranged from those that save more resources than they cost, to those costing more than 10 billion dollars per year of life saved. Overall, the median intervention costs $42,000 per life-year saved. The median medical intervention cost $19,000/life-year; injury reduction $48,000/life-year; and toxin control $2,800,000/life-year. Cost/life-year ratios and bibliographic references for more than 500 life-saving interventions are provided.

Entities:  

Mesh:

Year:  1995        PMID: 7604170     DOI: 10.1111/j.1539-6924.1995.tb00330.x

Source DB:  PubMed          Journal:  Risk Anal        ISSN: 0272-4332            Impact factor:   4.000


  145 in total

1.  Costs in Perspective: Understanding Cost-Effectiveness Analysis.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

Review 2.  Cost utility analysis of radiographic screening for an orbital foreign body before MR imaging.

Authors:  D J Seidenwurm; C H McDonnell; N Raghavan; J Breslau
Journal:  AJNR Am J Neuroradiol       Date:  2000-02       Impact factor: 3.825

3.  Development of the health and economic consequences of smoking interactive model.

Authors:  M E Orme; S L Hogue; L M Kennedy; A C Paine; C Godfrey
Journal:  Tob Control       Date:  2001-03       Impact factor: 7.552

4.  Guidance for commissioners on the cost effectiveness of smoking cessation interventions. Health Educational Authority.

Authors:  S Parrott; C Godfrey; M Raw; R West; A McNeill
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

5.  Smoking cessation guidelines for health professionals. A guide to effective smoking cessation interventions for the health care system. Health Education Authority.

Authors:  M Raw; A McNeill; R West
Journal:  Thorax       Date:  1998-12       Impact factor: 9.139

Review 6.  Pharmacoeconomics of influenza vaccination in the elderly: reviewing the available evidence.

Authors:  M J Postma; R M Baltussen; M L Heijnen; L T de Berg; J C Jager
Journal:  Drugs Aging       Date:  2000-09       Impact factor: 3.923

Review 7.  Interferon gamma-1b therapy for cryptogenic fibrosing alveolitis.

Authors:  J Britton
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

Review 8.  AIDS policy modeling for the 21st century: an overview of key issues.

Authors:  M S Rauner; M L Brandeau
Journal:  Health Care Manag Sci       Date:  2001-09

9.  Comparative efficiency of national health systems: cross national econometric analysis.

Authors:  D B Evans; A Tandon; C J Murray; J A Lauer
Journal:  BMJ       Date:  2001-08-11

Review 10.  Applications of economic models in healthcare: the introduction of pioglitazone in Sweden.

Authors:  Freddie Henriksson
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.